Core Viewpoint - Equasens, a leader in digital healthcare solutions, has announced its financial calendar for the 2026 financial year, detailing key dates for revenue and results announcements [1]. Group 1: Financial Calendar - 2025 annual revenue will be reported on February 5, 2026, after market close [2] - 2025 annual results will be released on March 30, 2026, before market opens [2] - 2026 Q1 revenue is scheduled for April 29, 2026, after market close [2] - The Annual General Meeting will take place on June 25, 2026 [2] - 2026 Half-year revenue will be announced on July 30, 2026, after market close [2] - 2026 Half-year results will be available on September 28, 2026, before market opens [2] - 2026 Q3 revenue will be reported on October 29, 2026, after market close [2] Group 2: Company Overview - Equasens Group has been established for over 35 years and currently employs more than 1,400 people across Europe [3] - The Group specializes in digital healthcare solutions that support healthcare professionals in their daily operations, including electronic equipment, digital solutions, and healthcare robotics [4] - Equasens is recognized for its interoperability solutions that enhance coordination among healthcare professionals, improving patient care and the efficiency of the healthcare system [5]

Core Points - Equasens Group announces the departure of Damien Valicon as Deputy Chief Executive Officer and Director of the Pharmagest Division, with François-Pierre Marquier appointed as his successor [2][3] - François-Pierre Marquier has been with Pharmagest since May 2021 and has held various leadership roles, including overseeing the Pharmacy France business since January 2023 [4] - The transition period for François-Pierre Marquier's appointment will be effective after approval from the Board of Directors [3] Company Overview - Equasens Group, founded over 35 years ago, is a leader in digital healthcare solutions, employing over 1,400 people across Europe [6] - The company specializes in business applications that support healthcare professionals in their daily operations, including electronic equipment, digital solutions, and healthcare robotics [7] - Equasens Group aims to improve coordination among healthcare professionals through interoperability solutions, enhancing patient care and system efficiency [8] Strategic Direction - The company follows a two-pronged development strategy that combines organic growth with targeted acquisitions at a European level [9] - Upcoming financial communications include Q2 2025 revenue on July 31, 2025, and H1 2025 results on September 26, 2025 [11]

Core Points - Equasens Group will hold its Annual Ordinary General Meeting on June 25, 2025, at 5:30 PM at its registered office in Villers-lès-Nancy [2] - The agenda and resolutions for the meeting were published in the French legal announcements on May 16, 2025 [3] - The Meeting Notice was published on June 6, 2025, detailing participation and voting procedures [4] Company Information - Equasens Group, founded over 35 years ago, is a leader in digital healthcare solutions, employing over 1,300 people across Europe [8] - The company provides specialized business applications that support healthcare professionals in various settings, including private practice and healthcare establishments [9] - Equasens Group focuses on interoperability solutions that enhance coordination among healthcare professionals, improving patient care and system efficiency [10] Meeting Logistics - The Annual General Meeting will be broadcast live online, with connection information available 48 hours prior to the meeting [7] - A replay of the meeting will also be accessible on the company's website for later viewing [7] - All relevant documents and voting forms are available on the company's website since June 4, 2025 [5]

Core Viewpoint - QHSLab Inc. is in advanced discussions for a strategic restructuring with Catheter Precision, Inc. to enhance financial flexibility and long-term growth outlook [1][7]. Financial Restructuring - The restructuring aims to significantly improve QHSLab's financial position by reducing near-term payment obligations, increasing the conversion price of existing debt instruments, and removing default-related overhang [2][8]. - The anticipated agreement will introduce a payment-in-kind (PIK) interest option and extend the maturity of the notes, allowing the company to redirect capital toward key growth initiatives [2][3]. Expected Benefits - The restructuring is expected to support growth and add value for shareholders, representing a major step toward long-term financial strength [3]. - The company plans to finalize the agreement and issue a formal announcement in the coming weeks [3]. Company Overview - QHSLab, Inc. provides digital healthcare solutions and point-of-care diagnostic tests to primary care physicians, utilizing advanced artificial intelligence algorithms for patient assessment and monitoring [5]. - The company's products are designed to improve patient monitoring and medical care while increasing revenues for physicians [5].